# Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network

Ross D. Williams<sup>1,†</sup> MSc, Aniek F. Markus<sup>1,†</sup> MSc, Cynthia Yang<sup>1</sup> MSc, Talita Duarte Salles<sup>2</sup> PhD, Thomas Falconer<sup>3</sup> MS, Jitendra Jonnagaddala<sup>4</sup> PhD, Chungsoo Kim<sup>5</sup> PharmD, Dr. Yeunsook Rho<sup>6</sup> PhD, Andrew Williams<sup>7</sup> PhD, Min Ho An<sup>8</sup> MD, María Aragón<sup>2</sup> PhD, Carlos Areia<sup>9</sup> MSc, Edward Burn<sup>2,10</sup> PhD, Young Hwa Choi<sup>11</sup> MD PhD, Iannis Drakos<sup>12</sup> PhD, Maria Tereza Fernandes Abrahão<sup>13</sup> PhD, Sergio Fernández-Bertolín<sup>2</sup> MSc, George Hripcsak<sup>3</sup> MD, Benjamin Skov Kaas-Hansen<sup>14,15</sup> MD, Prasanna L Kandukuri<sup>16</sup> MS, Jan A. Kors<sup>1</sup> PhD, Kristin Kostka<sup>17</sup> MPH, Siaw-Teng Liaw<sup>4</sup> MBBS PhD, Rae Woong Park<sup>18</sup> MD, PhD, Nicole Pratt<sup>19</sup> PhD, Gerardo Machnicki<sup>20</sup> PhD, Daniel Morales<sup>21</sup> PhD, Fredrik Nyberg<sup>22</sup> MD PhD, Albert Prats-Uribe<sup>10</sup> MPH, Gowtham Rao<sup>23</sup> PhD MD PhD, Christian G. Reich<sup>17</sup> MD PhD, Marcela Rivera<sup>24</sup> PhD, Tom Seinen<sup>1</sup> MSc, Azza Shoaibi<sup>23</sup> MPH PhD, Matthew E Spotnitz<sup>3</sup> MD, Ewout W. Steyerberg<sup>25,26</sup> PhD, Marc A. Suchard<sup>27</sup> MD PhD, Seng Chan You<sup>18</sup> MD, Lin Zhang<sup>28,29</sup> MD PhD, Lili Zhou<sup>16</sup> PhD, Patrick B. Ryan<sup>23</sup> PhD, Daniel Prieto-Alhambra<sup>10</sup> MD PhD, Jenna M. Reps<sup>23,&</sup> PhD, Peter R. Rijnbeek<sup>1,&,\*</sup> PhD

<sup>&</sup>lt;sup>1</sup>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>&</sup>lt;sup>2</sup>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)

<sup>&</sup>lt;sup>3</sup>Department of Biomedical Informatics, Columbia University, New York, NY

<sup>&</sup>lt;sup>4</sup>School of Public Health and Community Medicine, UNSW Sydney

<sup>&</sup>lt;sup>5</sup>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea

<sup>&</sup>lt;sup>6</sup>Department of Bigdata, Health Insurance Review & Assessment Service, Republic of Korea

<sup>&</sup>lt;sup>7</sup>Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, 02111, USA

<sup>8</sup>So Ahn Public Health Center, Wando County Health Center and Hospital, Wando, Republic of Korea

<sup>&</sup>lt;sup>9</sup>Nuffield Department of Clinical Neurosciences, University of Oxford

<sup>&</sup>lt;sup>10</sup>Centre for Statistics in Medicine, NDORMS, University of Oxford

<sup>&</sup>lt;sup>11</sup>Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea

<sup>&</sup>lt;sup>12</sup>Center for Surgical Science, Koege, Denmark

<sup>&</sup>lt;sup>13</sup>Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

<sup>&</sup>lt;sup>14</sup>Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark

<sup>&</sup>lt;sup>15</sup>NNF Centre for Protein Research, University of Copenhagen, Denmark

<sup>&</sup>lt;sup>16</sup>Abbvie, Chicago, United States

<sup>&</sup>lt;sup>17</sup>Real World Solutions, IQVIA, Cambridge, MA, United States

<sup>&</sup>lt;sup>18</sup>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea

<sup>&</sup>lt;sup>19</sup>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia

<sup>&</sup>lt;sup>20</sup>Janssen Latin America, Buenos Aires, Argentina

<sup>&</sup>lt;sup>21</sup>Division of Population Health and Genomics, University of Dundee, UK

<sup>&</sup>lt;sup>22</sup>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg, Sweden

<sup>&</sup>lt;sup>23</sup>Janssen Research & Development, Titusville, NJ, USA

<sup>&</sup>lt;sup>24</sup>Bayer Pharmaceuticals, Bayer Hispania, S.L., Barcelona, Spain

<sup>&</sup>lt;sup>25</sup>Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

†These authors contributed equally as co-first authors.

<sup>&</sup>These authors contributed equally as co-last authors.

\* Corresponding author

E-mail: p.rijnbeek@erasmusmc.nl

#### **Key Points**

**Question:** Can we, by combining socio-demographics and medical history, identify people at high risk of severe forms of disease were they to contract COVID-19 infection?

**Findings:** The COVID-19 Estimated Risk (COVER) models demonstrated good discrimination and calibration in predicting hospitalization, intensive services, and death for patients with COVID-19, and were successfully applied across populations in US, Europe and Asia.

**Meaning:** Personalized risk predictions for COVID-19 outcomes are possible and can be used to inform individual behavioural choices and help design shielding strategies during deconfinement.

<sup>&</sup>lt;sup>26</sup>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

<sup>&</sup>lt;sup>27</sup>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA

<sup>&</sup>lt;sup>28</sup>School of Public Health, Peking Union Medical College, Beijing, China;

<sup>&</sup>lt;sup>29</sup>Melbourne School of Public Health, The University of Melbourne, Victoria, Australia.

#### **Abstract**

#### **Importance**

COVID-19 is causing high mortality worldwide. Developing models to quantify the risk of poor outcomes in infected patients could help develop strategies to shield the most vulnerable during de-confinement.

#### Objective

To develop and externally validate COVID-19 Estimated Risk (COVER) scores that quantify a patient's risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis.

#### Design

Multinational, distributed network cohorts.

#### Setting

We analyzed a federated network of electronic medical records and administrative claims data from 13 data sources and 6 countries, mapped to a common data model.

#### **Participants**

Model development used a patient population consisting of >2 million patients with a general practice (GP), emergency room (ER), or outpatient (OP) visit with diagnosed influenza or flu-like symptoms any time prior to 2020. The model was validated on patients with a GP, ER, or OP visit in 2020 with a confirmed or suspected COVID-19 diagnosis across four databases from South Korea, Spain and the United States.

#### **Outcomes**

Age, sex, historical conditions, and drug use prior to index date were considered as candidate predictors. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death, and iii) death in the 30 days after index date.

#### Results

Overall, 43,061 COVID-19 patients were included for model validation, after initial model development and validation using 6,869,127 patients with influenza or flu-like symptoms. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, and kidney disease) which combined with age and sex could discriminate which patients would experience any of our three outcomes. The models achieved high performance in influenza. When transported to COVID-19 cohorts, the AUC ranges were, COVER-H: 0.73-0.81, COVER-I: 0.73-0.91, and COVER-F: 0.82-0.90. Calibration was overall acceptable, with overestimated risk in the most elderly and highest risk strata.

#### Conclusions and relevance

A 9-predictor model performs well for COVID-19 patients for predicting hospitalization, intensive services and death. The models could aid in providing reassurance for low risk patients and shield high risk patients from COVID-19 during de-confinement to reduce the virus' impact on morbidity and mortality.

## Introduction

The growing number of infections due to the Corona Virus Disease 2019 (COVID-19) has resulted in unprecedented pressure on healthcare systems worldwide, and a large number of casualties at a global scale. Although the majority of people have uncomplicated or mild illness (81%), some will develop severe disease leading to hospitalization and oxygen support (15%) or fatality (4%)<sup>1,2</sup>. The most common diagnosis in severe COVID-19 patients is pneumonia, other known complications include acute respiratory distress syndrome (ARDS), sepsis, or acute kidney injury (AKI)<sup>1</sup>. While there is currently no known cure or vaccine, the current approach to management of COVID-19 includes monitoring and controlling symptoms.

In response to the global pandemic, many countries have implemented measures aimed to reduce the average number of people a person with COVID-19 will infect<sup>3-6</sup>. The purpose of this was to ideally prevent the spread of the virus, or at least to slow the spread, a process known as flattening the curve<sup>7</sup>. However, strategies such as social distancing have impacted economies globally and economic worries are causing countries to consider lifting measures earlier than epidemiologists recommend<sup>8</sup>. There are worries that this may cause a second wave of infections, as seen historically in other pandemics<sup>9</sup>. Multiple governments are starting to release de-confinement strategies, for example the state of New York<sup>10</sup>, British<sup>11</sup>, and Dutch<sup>12</sup> governments have detailed plans to ease restrictions. However, they only concern populationlevel effects of likely disease spread and contain no information on how an individual's risk impacts their likely morbidity and mortality if they were to contract the virus. Research has shown that COVID-19 does not impact all ages and sexes equally 13 and as such a more personalised risk assessment can aid in improving outcomes. In a recent BMJ editorial<sup>14</sup>, the authors conclude that the COVID-19 response "is about protecting lives and communities most obviously at risk in our unequal society". Quantifying a patient's risk of having severe or critical illness when infected with COVID-19, could be used to help countries plan strategies to shield the most vulnerable patient populations. This is essential during the planning of deconfinement strategies.

The WHO Risk Communication Guidance distinguishes two categories of patients at high risk of severe disease: those older than 60 years and those with "underlying medical conditions" which is non-specific<sup>15</sup>. Using general criteria to assess the risk of poor outcomes is a crude risk discrimination mechanism as entire patient groupings are treated homogeneously ignoring individual differences. Prediction models can quantify a patient's individual risk and data-driven methods could identify risk factors that have been previously overlooked. The number of studies developing prediction models for COVID-19 is still limited and of insufficient quality, as suggested in a recent systematic review <sup>16</sup>. Previously published COVID-19 prediction models have been criticised for being i) poorly reported, ii) developed using small data samples, and iii) lacking external validation.

In this paper we aim to develop COVID-19 Estimated Risk (COVER) scores to quantify a patient's risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) due to COVID-19 using the Observational Health Data Sciences and Informatics (OHDSI) Patient-Level Prediction framework<sup>17</sup>. The research collaboration known as OHDSI has developed standards and tools that allow patient-level prediction models to be developed and externally validated rapidly following accepted best practices<sup>18</sup>. This allows us to overcome the previously identified shortcomings of previous COVID-19 prediction papers by reporting according to open science standards and implementing widespread external validation. To overcome the shortcoming of using small data for development, we made use of the abundant data from patients with influenza or flu-like symptoms to develop the models and then we tested whether the models transport to COVID-19 patients. Given the symptomatic similarities between the two diseases we hypothesized that the developed models will be able to transport between the two problem settings.

#### Methods

We performed a retrospective cohort study to develop COVID-19 prediction models for severe and critical illness.

#### Source of data

This study used observational healthcare databases from six different countries. All datasets used in this paper were mapped into the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM)<sup>19</sup>. The OMOP-CDM was developed for researchers to have diverse datasets in a consistent structure and vocabulary. This enables analysis code and software to be shared among researchers which facilitates external validation of the prediction models.

#### Consent to publish

All databases obtained IRB approval or used deidentified data that was considered exempt from IRB approval. Informed consent was not necessary at any site.

The OMOP-CDM datasets used in this paper are listed in Table 1.

#### **Participants**

For validation in COVID-19 we used a cohort of patients presenting at an initial healthcare provider interaction in a general practice (GP), emergency room (ER), or outpatient (OP) visit with COVID-19 disease. COVID-19 disease was identified by a diagnosis code for COVID-19 or a positive test for the SARS-COV-2 virus that was recorded after January 1st 2020. We required patients to be aged 18 or over, have at least 365 days of observation time prior to the index date and no diagnosis of influenza, flu-like symptoms, or pneumonia in the preceding 60 days.

Table 1 Data sources formatted to the OMOP-CDM used in this research

	Database			Contains COVI	D-
Database	Acronym	Country	Data type	19 data?	Time period
Optum© De-Identified	ClinFormatics	US	Claims	No	2000-2018
Clinformatics® Data Mart					
Database					
Columbia University	CUIMC	US	EMR	Yes	Influenza: 1990-2020
Irving Medical Center					COVID-19: March-April
Data Warehouse					2020
Health Insurance and	HIRA	South Korea	Claims	Yes	COVID-19: 1st January–4th
Review Assessment					April 2020
The Information System	SIDIAP	Spain	GP and hospital	Yes	Influenza: 2006-2017
for Research in Primary			admission EHRs		COVID-19: March 2020
Care			linked		
Tufts Research Data	TRDW	US	EMR	Yes	Influenza: 2006-2020
Warehouse					COVID-19: March 2020
Ajou University School of	AUSOM	South Korea	EHR	No	1996 - 2018
Medicine Database					
Australian Electronic	AU-ePBRN	Australia	GP and hospital	No	2012-2019
Practice based Research			admission EHRs		
Network			linked		
IBM MarketScan®	CCAE	US	Claims	No	2000-2018
Commercial Database					
Integrated Primary Care	IPCI	Netherlands	GP	Yes	2006-2020
Information					
Japan Medical Data	JMDC	Japan	Claims	No	2005-2018
Center					
IBM MarketScan® Multi-	MDCD	US	Claims	No	2006-2017
State Medicaid Database					
IBM MarketScan®	MDCR	US	Claims	No	2000-2018
Medicare Supplemental					
Database					
Optum <sup>©</sup> de-identified	Optum EHR	US	Claims	No	2006-2018
Electronic Health Record					
Dataset					

For model development, we identified patients over 18 with a GP, ER, or OP visit with influenza or flu-like symptoms (e.g. fever and either cough, shortness of breath, myalgia, malaise, or fatigue), at least 365 days of prior observation, and no symptoms in the preceding 60 days.

#### Outcome

We investigated three outcomes of COVID-19: 1) hospitalization with pneumonia from index up to 30 days after index, 2) hospitalization with pneumonia that required intensive services or death after hospitalization with pneumonia from index up to 30 days after index, and 3) death from index up to 30 days after index.

The full details of the participant cohorts and outcomes used for development and validation can be found in the study package.

#### **Predictors**

When using a data-driven approach to model development, generally the resulting models contain a large number of predictors. We developed a data-driven model using age in groups (18-19, 20-25, 26-30, ..., 95+), sex and binary variables indicating the presence or absence of recorded conditions and drugs any time prior to index. In total, we derived 31,917 candidate predictors indicating the presence of the 31,917 unique conditions/drugs recorded prior to the index date (GP, ER, or OP visit) for each patient. This may optimise performance, but a large number of predictors can be a barrier to clinical implementation. The utility of models for COVID-19 requires that they can be widely implemented across worldwide healthcare settings. Therefore, in addition to a data-driven model, we investigated two models that include fewer candidate predictors.

The age/sex model used age groups and sex as candidate predictors. The COVER models included 7 candidate predictors, in addition to age groups and sex, that corresponded to the following conditions existing any time prior to the index date (GP, ER, or OP visit): cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia and kidney disease (chronic and acute). Full details on how these 7 predictors were created can be found in Appendix A.

#### Sample Size

The models were developed using the Optum<sup>©</sup> De-Identified Clinformatics<sup>®</sup> Data Mart Database. We identified 7,344,117 valid visits with influenza or flu-like symptoms, of which 4,431,867 were for patients aged 18 or older, 2,977,969 of these had >= 365 days observation prior to the visit, and 2,082,277 of these had no prior influenza/symptoms/pneumonia in the 60 days prior to index. We selected a stratified sample of 150,000 patients from the total population to efficiently develop models to address the current pandemic, while preserving the outcome rate.

#### Statistical analysis methods

Model development followed a previously validated and published framework for the creation and validation of patient-level prediction<sup>17</sup>. We used a person 'train-test split' method to perform internal validation. In each development cohort, a random split sample (`training sample') containing 75% of patients was used to develop the prediction models and the remaining 25% of patients (`test sample') was used to validate the models. We trained models using LASSO regularised logistic regression, using a 3-fold cross validation technique in the influenza training sample to learn the optimal regularization hyperparameter through an adaptive search<sup>20</sup>. We used R (version 3.6.3) and the OHDSI Patient-Level Prediction package (version 3.0.16) for all statistical analyses<sup>17</sup>.

To evaluate the performance, we calculate the overall discrimination of the model using the area under the receiver operating characteristic curve (AUC), the area under the precision recall-curve (AUPRC), and the model calibration. The AUC indicates the probability that for two randomly selected patients, the patient who gets the outcome will be assigned a higher risk. The AUPRC shows the trade-off between identifying all patients who get the outcome (recall) versus incorrectly identifying patients without outcome (precision) across different risk thresholds. The model calibration is presented in a plot to examine agreement between predicted and observed risks across deciles of predicted risk. Calibration assessment is then performed visually rather than using a statistic or numeric value as this provides a better impression of the direction and scale of miscalibration<sup>21</sup>. Summary statistics are reported from the test samples.

We performed two types of external validation. A classical external validation in which we applied the models to identical settings across diverse patient populations with influenza or flulike symptoms prior to 2020 not used to develop the model, and a specific COVID-19 validation for databases containing COVID-19 data. To do this we assessed patients with confirmed COVID-19 in 2020. We examined the external validation using AUC, AUPRC and model calibration in the same way as internally.

This study was conducted and reported according to the Transparent Reporting of a multivariate prediction model for Individual Prediction or Diagnosis (TRIPOD) guidelines<sup>22</sup> and adhered to the open science principals for publicly prespecifying and tracking changes to study objectives, protocol and code as described in the Book of OHDSI<sup>23</sup>. For transparency, the study package for the development and external validation of the models in any database with OMOP-CDM is available on GitHub at:

https://github.com/ohdsi-studies/Covid19PredictionStudies.

## Results

#### Online results

The complete results are available as an interactive app at:

http://evidence.ohdsi.org/Covid19CoverPrediction

#### **Participants**

Table 2 describes the characteristics at baseline of the patients across the different databases used for development and external validation. Out of the 150,000 patients sampled with influenza or flu-like symptoms in the development database (ClinFormatics), there were 6,712 patients requiring hospitalization with pneumonia, 1,828 patients requiring hospitalization and intensive services with pneumonia, and 748 patients died within 30 days. See Table 2 for the full outcome rates across the databases included in this study. A total of 43,061 participants with COVID-19 disease were further included for external validation.

11

In the databases used for external validation, the patient numbers ranged from 395 (TRDW) to 3,146,743 (CCAE). The datasets had varied outcome rates ranging from 0.06-12.47 for hospital admission, 0.01-4.91 for intensive services, and 0.01-12.27 for death. Characteristics at baseline differed substantially between databases as can be seen in Table 2, with MDCR (a database representing retirees) containing a relatively old population of patients and a high number of comorbidities, and IPCI (a database representing general practice) showing a relatively low condition occurrence.

#### Model specification


The data-driven models for hospitalization, intensive services, and death contained 521, 349, and 205 predictors respectively. The COVER-H, COVER-I, and COVER-F scores are presented in Figure 1. These models are also accessible online:

http://evidence.ohdsi.org/Covid19CoverPrediction.


Figure 1 also provides a risk converter, which allows for easy conversion between the risk score and predicted risk of the outcomes. Furthermore, we provide a plot of the probability distribution for the three models from patients in ClinFormatics to demonstrate the expected regions the probabilities fall into. To calculate the COVER scores using Figure 1, a clinician needs to identify which predictors the patient has. The points for each of those predictors are then added to arrive at the total score. For example, if a 63-year-old female patient has diabetes and heart disease, then her risk score for hospital admission (COVER-H) is 43 (female sex) + 4 (heart disease) + 3 (diabetes) + 15 (age) = 65. The risk scores for intensive services (COVER-I) and fatality (COVER-F) are 51 and 47, respectively.

Table 2 Population size, outcome rates and characteristics for the development database (influenza) and external validation in COVID-19 and influenza (N/A indicates this result is not available)

	Developm External validation: COVID-19					External validation: influenza								
	ent													
	ClinForma	CUIMC	HIRA	SIDIAP	TRDW	AUSOM	AU-	CCAE	IPCI	JMDC	MDCD	MDCR	Optum EHR	
	tics						ePBRN							
Number of participants	2,082,277	2,731	1,985	37,950	395	3,105	2,791	3,146,8	29,132	1,276,47	536,806	248,98	1,654,157	
								01		8		9		
Hospitalization with	105,030	N/A	89	1,223	21	49	29	33,824	22	728	32,987	31,059	34,229	
oneumonia (Outcome rate	(5.04)		(4.48)	(1.11)	(5.32)	(1.58)	(1.04)	(1.07)	(0.08)	(0.06)	(6.15)	(12.47)	(2.07)	
%)														
Hospitalization with	29,905	134	22	N/A	5	5	3	4,856	24	65	7,226	3,628	7,368	
oneumonia requiring	(1.44)	(4.91)	(1.11)		(1.27)	(0.16)	(0.11)	(0.02)	(0.08)	(0.01)	(1.35)	(1.46)	(0.45)	
ntensive services or death														
(Outcome rate %)														
Death	11,407	335	43	406	1	5	4	965	24	75	2,603	1,354	3,513	
(Outcome rate %)	(0.55)	(12.27)	(2.17)	(1.07)	(0.25)	(0.16)	(0.14)	(0.03)	(0.08)	(0.01)	(0.48)	(0.54)	(0.21)	
Age (% above 65)	26.1	38.9	15.6	17.9	18.2	11.9	23.1	12.5	16.9	16.0	14.2	96.2	30.0	
Sex (%, male)	44.4	47.2	43.5	43.4	49.6	41.7	44.5	42.7	43.7	56.8	29.2	45.9	40.1	
Cancer (%)	12.6	17.1	9.8	6.3	11.6	7.7	8.2	6.2	3.7	2.5	8.9	35.2	10.6	
COPD (%)	10.2	9.3	4.9	2.5	6.3	2.7	3.1	2.7	2.7	0.5	19.8	26.6	7.6	
Diabetes (%)	20.5	30.9	23.1	8.0	19.7	3.8	13.0	11.4	6.7	8.3	27.4	36.1	15.3	
Heart disease (%)	31.0	40.1	17.1	11.2	25.8	7.7	12.9	16.5	7.5	8.0	36.1	68.2	23.4	
Hypertension (%)	44.2	51.6	26.3	14.8	38.5	13.9	27.0	29.1	12.4	11.4	49.8	80.4	36.1	
Hyperlipidemia (%)	46.8	40.6	39.9	11.4	32.9	3.3	20.2	21.8	4.6	15.2	36.0	69.6	34.2	
(idney disease (%)	18.7	31.2	17.0	11.0	24.3	7.6	6.2	9.0	1.2	5.1	23.4	35.5	14.9	



**D** LEARN THE RISKS



Risk Score probability distributions in ClinFormatics

A digital version of this risk calculator is available in: http://evidence.ohdsi.org/ Covid19CoverPrediction




Figure 1 The COVER Scores, Risk Converter, and Risk Score probability distributions in ClinFormatics

#### Model performance

The internal validation performance for each model is presented in Table 4. The external validation of the COVER scores on the COVID-19 patients is shown in Table 5. Full validation results can be seen in Appendix B. Receiver operating characteristic and calibration plots are included in Appendix C.

Table 3 The results for internal validation in ClinFormatics

Outcome	Predictors	No. Variables	AUC	AUPRC
Hospitalization with pneumonia	Conditions/drugs + age/sex	521	0.852	0.224
	Age/sex	2	0.818	0.164
	COVER-H	9	0.840	0.120
Hospitalization with pneumonia requiring	Conditions/drugs + age/sex	349	0.860	0.070
intensive services or	Age/sex	2	0.821	0.049
death	COVER-I	9	0.839	0.059
Death	Conditions/drugs + age/sex	205	0.926	0.069
	Age/sex	2	0.909	0.037
	COVER-F	9	0.896	0.039

Table 4 COVID-19 validation of the COVER-H, COVER-I, and COVER-F models on COVID-19 patients with a GP, ER, or OP visit in 2020 (\*Confidence interval is not reported as the number of outcomes is larger than 1000)

Outcome	Database	AUC (95% confidence interval)	AUPRC
Hospitalization	HIRA	0.806 (0.762-0.851)	0.134
with pneumonia	SIDIAP	0.748*	0.072
	TRDW	0.731 (0.611-0.851)	0.132
Hospitalization with pneumonia requiring intensive services or death	CUIMC	0.734 (0.699-0.769)	0.100
	HIRA	0.910 (0.889-0.931)	0.053
Death	CUIMC	0.820 (0.796-0.840)	0.400
	HIRA	0.898 (0.857-0.940)	0.150
	SIDIAP	0.895 (0.881-0.910)	0.083

## Discussion

#### Interpretation

We developed and externally validated models using large datasets of influenza patients to quantify a patient's risk of developing severe or critical illness due to COVID-19. In the development data, the 9-predictor COVID-19 Estimated Risk (COVER) scores were a good tradeoff between model complexity and performance, as the AUCs were generally close to the large data-driven models. The COVER scores achieved an AUC of 0.84 when predicting which patients will be hospitalized or require intensive services and an AUC of 0.9 when predicting which patients will die within 30 days. When validated on 1,985 COVID-19 patients in South Korea the COVER-H score performed well (AUC > 0.8), and COVER-I and COVER-F performed excellently (AUC ≥ 0.9). The model performed similarly well when applied to 37,950 COVID-19 Spanish patients (COVER-H: AUC 0.75) and excellent performance when predicting death (COVER-F: AUC 0.89). A visual assessment of calibration plots across validations showed reasonable calibration in both SIDIAP and HIRA. There was slight overestimation of risk amongst oldest and highest risk strata in SIDIAP and to a lesser extent in HIRA. When applied to CUIMC the COVER-I and COVER-F models achieved good AUCs of 0.73 and 0.82, respectively. The calibration was poor in CUIMC, often underestimating risk, but this may be due to CUIMC containing mostly hospitalized COVID-19 patients, so the CUIMC cohort are sicker. Given the calibration was good for the vast majority of patients, recalibration was not deemed necessary for transporting the model to COVID-19 patients. We also performed sensitivity analyses using more sensitive COVID-19 definitions which also included patients with symptoms, or symptoms and influenza. The results did not show much deviation from the specific definition (see Appendix B).

These results showed that training in large historical influenza data was an effective strategy to develop models for COVID-19 patients. We also validated the age/sex and data-driven models on the COVID-19 patients and the age/sex models already appear to do well. This shows that age and sex are strong predictors of disease severity in COVID-19. Our results show that quantifying a symptomatic patient's risk based on a small selection of comorbidities as well as age/sex gives improved model performance.

We identified one other model that addressed a similar problem setting. The COVID-19 Vulnerability Index built from a 5% sample of Medicare claims data from 2015-2016 using a proxy for COVID-19. The model predicts hospitalization due to pneumonia (except when caused by tuberculosis), influenza, acute bronchitis, or other specified upper respiratory infections<sup>24</sup>. The model achieved an AUC of 0.73, but has not been validated on a COVID-19 cohort. Several other models have been proposed to predict severity of COVID-19<sup>25-27</sup>, but these only consider patients already hospitalized.

#### Limitations

Limitations of the study included being unable to develop a model on COVID-19 patient data due to the scarcity of databases that contain this information in sufficient numbers, however we were able to validate the models developed and as such are confident the performance is transportable. In CUIMC, HIRA and SIDIAP COVID-19 data we reached the threshold for reliable external validation<sup>28,29</sup>. The results of TRDW are promising, but might not be reliable due to the low number of outcomes. As larger COVID-19 databases become available, training a model using this data may highlight predictors of severity amongst uncommon influenza presentations, for example younger and healthier patients experiencing severe or critical illness. Further limitations include misclassification of predictors, for example if disease is incorrectly recorded in a patient's history, as well as in the cohorts through incorrect recording of influenza or COVID-19. We were unable to validate the COVER-H model in CUIMC as it mostly contained ER or hospitalized COVID-19 patients and the COVER-I model in SIDIAP due to a lack of information on intensive services in the database.

#### **Implications**

The results show we were able to develop models that use a patient's socio-demographics and medical history to predict their risk of becoming severely or critically ill when infected with COVID-19. To our knowledge, this is the first study that has been able to extensively externally validate prediction models on COVID-19 patients internationally. The strong performance in COVID-19 patients of the COVER scores can be used to identify patients who should be shielded

from COVID-19. This can have multiple benefits; i) it can help reassure low risk people who may be psychologically impacted by the stress of the virus, and ii) it can help identify which people would be at increased risk of severe or critical outcomes and as such should continue to be shielded during the first stages of de-confinement.

Conclusion

In this paper we developed and validated models that can predict which patients presenting with COVID-19 are at high risk of experiencing severe or critical illness. These models can be used to identify vulnerable patient populations that require shielding as they have the worst COVID-19 prognosis. This evidence can be particularly impactful as governments start to lift measures and should be used to aid strategic planning to help us protect the most vulnerable.

Acknowledgements

The authors would like to thank the OHDSI community for their contributions to the tools used for this analysis.

The authors appreciate healthcare professionals dedicated to treating COVID-19 patients in Korea, and the Ministry of Health and Welfare and the Health Insurance Review & Assessment Service of Korea for sharing invaluable national health insurance claims data in a prompt manner.

**Funding** 

This project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

18

This project is funded by the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en Salut.

The University of Oxford received a grant related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201), and partial support from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre.

DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

AP-U is supported by Fundacion Alfonso Martin Escudero and the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1).

BSKH is funded through Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001).

This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992].

This project is part funded by the UNSW RIS grant.

## **Author contributions**

All authors made substantial contributions to the conception or design of the work; JMR and RDW led the data analysis; all authors were involved in the analysis and interpretation of data for the work; all authors have contributed to the drafting and revising critically the manuscript

19

for important intellectual content; all authors have given final approval and agree to be accountable for all aspects of the work.

## **Competing interests**

All authors have filled and provided an ICMJE form with any potential competing interests.

## References

- 1. World Health Organization. *Clinical management of severe acute respiratory infection*(SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva:
  World Health Organization;2020.
- 2. Prieto-Alhambra D, Ballo E, Coma-Redon E, et al. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. *medRxiv.* 2020:2020.2005.2004.20090050.
- Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? *The Lancet*. 2020;395(10228):931-934.
- 4. Department of Health And Social Care. Coronavirus action plan: a guide to what you can expect across the UKCoronavirus: action plan. Department of Health. https://www.gov.uk/government/publications/coronavirus-action-plan/coronavirus-action-plan-a-guide-to-what-you-can-expect-across-the-uk. Published: March 2020, Accessed May 25, 2020In:2020.5. Lee VJ, Chiew CJ, Khong WX. Interrupting transmission of COVID-19: lessons from containment efforts in Singapore. J Travel Med. 2020.
- 6. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. *JAMA*. 2020.
- 7. Saez M, Tobias A, Varga D, Barceló MA. Effectiveness of the measures to flatten the epidemic curve of COVID-19. The case of Spain. *Sci Total Environ*. 2020;727:138761.
- 8. Thunström L, Newbold SC, Finnoff D, Ashworth M, Shogren JF. The benefits and costs of using social distancing to flatten the curve for COVID-19. *Journal of Benefit-Cost Analysis*. 2020:1-27.

- 9. Markel H, Lipman HB, Navarro JA, et al. Nonpharmaceutical Interventions Implemented by US Cities During the 1918-1919 Influenza Pandemic. *JAMA*. 2007;298(6):644-654.
- 10. New York State. NY FORWARD: A guide to reopening New York & building back better. New York State. https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/NYForwardReope ningGuide.pdf. Published: May 2020. Accessed May 25 2020 2020.11.
- 11. UK Government, Cabinet Office. Our plan to rebuild: The UK Government's COVID-19 recovery strategy. UK Government. https://www.gov.uk/government/publications/our-plan-to-rebuild-the-uk-governments-covid-19-recovery-strategy/our-plan-to-rebuild-the-uk-governments-covid-19-recovery-strategy. Published May 2020. Accessed May 25 2020 2020.
- 12. Rijksoverheid. Factsheet versoepelen maatregelen corona. Rijksoverheid. https://www.rijksoverheid.nl/documenten/publicaties/2020/05/06/factsheet-maatregelen-corona. Published May 2020. Accessed May 25 2020.
- 13. Burn E, You SC, Sena A, et al. An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza.

  medRxiv. 2020:2020.2004.2022.20074336.
- 14. Scally G, Jacobson B, Abbasi K. The UK's public health response to covid-19. *BMJ*. 2020;369:m1932.
- 15. World Health Organization. *Coronavirus disease 2019 (COVID-19) Situation report 51 2020, 11 March 2020.* World Health Organization;2020.
- 16. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ*. 2020;369:m1328.
- 17. Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. *J Am Med Inform Assoc.* 2018;25(8):969-975.
- 18. Reps JM, Williams RD, You SC, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network:

- validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. *BMC Med Res Methodol.* 2020;20(1):102-102.
- 19. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc.* 2012;19(1):54-60.
- 20. Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. *ACM Transactions on Modeling and Computer Simulation (TOMACS)*. 2013;23(1):1-17.
- 21. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur Heart J.* 2014;35(29):1925-1931.
- 22. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med.* 2015;162(1):W1-73.
- 23. Observational Health Data Sciences and Informatics. *The Book of OHDSI.* 2019.
- 24. DeCaprio D, Gartner J, Burgess T, Kothari S, Sayed S. Building a COVID-19 Vulnerability Index. *arXiv preprint arXiv:200307347.* 2020.
- 25. Liang W, Liang H, Ou L, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Internal Medicine*. 2020.
- 26. Xiao L-s, Zhang W-F, Gong M, et al. Development and Validation of the HNC-LL Score for Predicting the Severity of Coronavirus Disease 2019. *Available at SSRN 3572843*. 2020.
- 27. Ji D, Zhang D, Xu J, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. *Clin Infect Dis.* 2020.
- 28. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JDF. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. *J Clin Epidemiol*. 2005;58(5):475-483.
- Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. *Stat Med.* 2016;35(2):214-226.

## Appendix A: COVER score derivation

The go from the data-driven model to the model with reduced variables we implemented this process for each of the scores.

- 1. A clinician inspected the data-driven model to identify variables that had a high standardized mean difference between those who with and without outcome. For example, often there are multiple predictors which are related and correlated selected by the model, for example a model might select as associated a condition occurrence in different time periods predating the index date. This could be simplified to a predictor saying only "Patient had condition X in history", rather than multiple predictors specifying within which the condition occurred, or multiple codes that are probably related to a specific condition. We identified general categories from these such as 'heart disease' and 'diabetes'.
- 2. Created phenotype definitions for each category.
- 3. Trained a LASSO logistic regression model on the original data using age groups, sex and newly created predictors indicating whether the patient had each category predictors.
- 4. Multiplied the coefficients of this reduced variable model by 10 and rounded to the nearest integer.
- 5. This gave us the simple score-based model.

The phenotypes for each COVER predictor are available in Supplement A.

# Appendix B: Full results

Table 5 External validation of the models on the target population of patients with influenza or flu-like symptoms any time prior to 2020 (N/A indicates this result is not available)

Outcome	Database	Condition age/sex	s/drugs +	Age/sex		COVER	
		AUC	AUPRC	AUC	AUPRC	AUC	AUPRC
Hospitalization	AUSOM	N/A	N/A	0.760	0.056	0.768	0.061
with	AU-ePBRN	N/A	N/A	N/A	N/A	0.756	0.031
pneumonia	CCAE	0.769	0.073	0.690	0.024	0.728	0.040
	IPCI	0.686	0.002	0.681	0.008	0.683	0.002
	JMDC	0.686	0.007	0.645	0.002	0.660	0.003
	MDCD	0.804	0.191	0.757	0.153	0.779	0.167
	MDCR	0.681	0.225	0.633	0.195	0.660	0.207
	Optum EHR	0.815	0.087	0.777	0.73	0.804	0.090
Hospitalization	AUSOM	0.896	0.216	0.770	0.010	0.783	0.028
with	AU-ePBRN	N/A	N/A	N/A	N/A	0.923	0.007
pneumonia	CCAE	0.816	0.020	0.718	0.004	0.774	0.009
requiring	IPCI	N/A	N/A	N/A	N/A	N/A	N/A
intensive	JMDC	0.778	0.002	0.708	0.000	0.750	0.001
services or	MDCD	0.802	0.048	0.741	0.030	0.773	0.037
death	MDCR	0.689	0.035	0.556	0.019	0.652	0.026
	Optum EHR	0.832	0.024	0.770	0.014	0.814	0.020
Death	AUSOM	0.812	0.017	0.793	0.007	0.798	0.008
	AU-ePBRN	N/A	N/A	N/A	N/A	0.893	0.007
	CCAE	0.833	0.016	0.780	0.001	0.806	0.002
	IPCI	0.866	0.020	0.856	0.008	0.859	0.008
	JMDC	0.766	0.001	0.723	0.000	0.724	0.001
	MDCD	0.842	0.027	0.823	0.022	0.829	0.022
	MDCR	0.678	0.014	0.598	0.008	0.627	0.009
	Optum EHR	0.889	0.024	0.867	0.018	0.872	0.016

Table 6 COVID-19 validation of the COVER-H, COVER-I, and COVER-F scores (N/A indicates this result is not available)

Outcome	Database	influenza or flu-like symptoms			influenza or f	Patients with COVID-19, influenza or flu-like symptoms in 2020			Patients with COVID-19 or symptoms in 2020			Patients with COVID-19 in 2020		
		Number of participants (Outcome rate %)	AUC	AUPRC	Number of participants (Outcome rate %)	AUC	AUPRC	Number of participants (Outcome rate %)	AUC	AUPRC	Number of participants (Outcome rate %)	AUC	AUPRC	
with HIRA pneumonia (COVER-H) SIDIA	CUIMC HIRA	N/A 58,072 (4.61)	N/A 0.767	N/A 0.132	N/A 48,057 (5.25)	N/A 0.762	N/A 0.143	N/A 47,594 (5.18)	N/A 0.763	N/A 0.142	N/A 1,985 (4.48)	N/A 0.806	N/A 0.134	
	SIDIAP	415,119 (0.12)	0.697	0.005	72,337 (1.82)	0.789	0.054	38,254 (3.21)	0.747	0.071	37,950 (3.223)	0.748	0.072	
	TRDW	6,725 (2.51)	0.723	0.064	1062 (3.01)	0.769	0.100	725 (3.72)	0.734	0.112	395 (5.32)	0.731	0.132	
Hospitalization with	CUIMC	27,356 (1.46)	0.778	0.043	4,337 (3.25)	0.777	0.081	3,354 (4.11)	0.756	0.093	2,731 (4.907)	0.734	0.1	
pneumonia requiring	HIRA	58,072 (0.85)	0.858	0.035	48,057 (1.00)	0.854	0.039	47,594 (1.01)	0.856	0.040	1,985 (1.11)	0.910	0.053	
intensive services ore	SIDIAP	415,119 (0.03)	0.775	0.003	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
death (COVER- I)	TRDW	6,725 (0.461)	0.769	0.018	1062 (0.471)	0.816	0.083	725 (0.690)	0.807	0.222	395 (1.27)	0.779	0.230	
Death (COVER-F)	CUIMC	27,356 (1.58)	0.847	0.082	4,337 (7.89)	0.843	0.32	3,354 (10.05)	0.834	0.377	2,731 (12.27)	0.82	0.4	
	HIRA	58,072 (2.28)	0.851	0.099	48,057 (2.75)	0.846	0.113	47,594 (2.78)	0.846	0.114	1,985 (2.17)	0.898	0.150	
	SIDIAP	415,119 (0.04)	0.885	0.010	72,337 (0.60)	0.919	0.068	38,254	0.895	0.082	37,950 (1.07)	0.895	0.083	
	TRDW	6,725 (0.074)	0.819	0.002	1062 (0.094)	0.970	0.015	725 (0.138)	0.971	0.023	395 (0.253)	0.959	0.030	

## Appendix C: Receiver operating characteristic and calibration plots

The figures below show the receiver operating characteristic and calibration plots for patients with COVID-19 in 2020, all plots are available online:

http://evidence.ohdsi.org/Covid19CoverPrediction.

